Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Earnings Data
Report Date
Feb 10, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.76Last Year’s EPS
0.48Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful market penetration of new treatments, particularly in the oncology segment. The advancement of zanzalintinib in clinical trials and its potential new indications were key positives. However, restructuring charges and potential regulatory delays posed challenges. Overall, the positive aspects outweigh the negatives, indicating a favorable outlook.Company Guidance
Strong Financial Performance
Exelixis reported total revenues of approximately $598 million for the third quarter of 2025, with cabozantinib franchise net product revenues of approximately $543 million, marking a 14% year-over-year increase.
Successful Launch and Growth in Neuroendocrine Tumors
CABOMETYX has rapidly become the market leader in second-line plus neuroendocrine tumors with greater than 40% new patient share for oral therapies.
Zanzalintinib Clinical Success
Positive results for STELLAR-303 in colorectal cancer (CRC) with a 20% reduction in the risk of death in the ITT population, marking the first clinical success in a non-MSI-high third-line plus CRC population.
Share Repurchase Program
Exelixis repurchased approximately $99 million of the company's shares in the third quarter, with an additional $750 million share repurchase program authorized.
EXEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EXEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $37.90 | $40.37 | +6.52% |
Jul 28, 2025 | $44.39 | $36.94 | -16.78% |
May 13, 2025 | $36.95 | $44.65 | +20.84% |
Feb 11, 2025 | $32.81 | $32.80 | -0.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Exelixis (EXEL) report earnings?
Exelixis (EXEL) is schdueled to report earning on Feb 10, 2026, After Close (Confirmed).
What is Exelixis (EXEL) earnings time?
Exelixis (EXEL) earnings time is at Feb 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EXEL EPS forecast?
EXEL EPS forecast for the fiscal quarter 2025 (Q4) is 0.76.